Search

Your search keyword '"Ozdemir, Feyyaz"' showing total 139 results
Start Over Author "Ozdemir, Feyyaz"
139 results on '"Ozdemir, Feyyaz"'

1. The results of adding immunotherapy to chemotherapy in patients with small cell lung cancer: Registurk-Lung study—Real-world data.

Author

Cil, Timucin, primary, Hacibekiroglu, Ilhan, additional, Uncu, Dogan, additional, Isikdogan, Abdurrahman, additional, Ates, Ozturk, additional, Sendur, Mehmet Ali Nahit, additional, Bilici, Mehmet, additional, Geredeli, Caglayan, additional, Turk, Haci Mehmet, additional, Cicin, Irfan, additional, Gumus, Mahmut, additional, Bilir, Cemil, additional, Ozcelik, Melike, additional, Coban, Ezgi, additional, Kilickap, Sadettin, additional, Demirag, Guzin, additional, Yildirim, Nilgun, additional, Ozdemir, Feyyaz, additional, Teker, Fatih, additional, and Altinbas, Mustafa, additional

Published
2024
Full Text
View/download PDF

2. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

Author

Yildirim, Hasan Cagri, primary, Kapar, Caner, additional, Koksal, Baris, additional, Seyyar, Mustafa, additional, Sanci, Pervin Can, additional, Guliyev, Murad, additional, Perkin, Perihan, additional, Buyukkor, Mustafa, additional, Yaslikaya, Sendag, additional, Majidova, Nargiz, additional, Keskinkilic, Merve, additional, Ozaskin, Duygu, additional, Avci, Tugay, additional, Gunes, Tugce Kubra, additional, Arcagok, Murat, additional, Topal, Alper, additional, Keskin, Gul Sema Yildiran, additional, Kavgaci, Gozde, additional, Yildirim, Nilgun, additional, Celayir, Ozde Melisa, additional, Avci, Nilufer, additional, Aslan, Ferit, additional, Alkan, Ali, additional, Erciyestepe, Mert, additional, Cengiz, Muhammet, additional, Pehlivan, Metin, additional, Gulmez, Ahmet, additional, Beypinar, Ismail, additional, Basoglu Tuylu, Tugba, additional, Kayikcioglu, Erkan, additional, Chalabiyev, Elvin, additional, Turhal, Serdal, additional, Guzel, Halil Goksel, additional, Ayas, Eyyup, additional, Sahbazlar, Mustafa, additional, Dulgar, Ozgecan, additional, Demir, Hacer, additional, Yavuzsen, Tugba, additional, Bayoglu, Vedat, additional, Kivrak Salim, Derya, additional, Ozturk, Banu, additional, Ozdemir, Feyyaz, additional, Kara, Oguz, additional, Oksuzoglu, Berna, additional, Bal, Oznur, additional, Demirci, Nebi Serkan, additional, Yilmaz, Mesut, additional, Cabuk, Devrim, additional, and Aksoy, Sercan, additional

Published
2024
Full Text
View/download PDF

4. Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study

Author

Yalcin, Suayib, Dane, Faysal, Oksuzoglu, Berna, Ozdemir, Nuriye Yildirim, Isikdogan, Abdurrahman, Ozkan, Metin, Demirag, Guzin Gonullu, Coskun, Hasan Senol, Karabulut, Bulent, Evrensel, Turkkan, Ustaoglu, Mehmet Ali, Ozdemir, Feyyaz, Turna, Hande, Yavuzsen, Tugba, Aykan, Faruk, Sevinc, Alper, Akbulut, Hakan, Yuce, Deniz, Hayran, Mutlu, and Kilickap, Saadettin

Published
2020
Full Text
View/download PDF

6. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: A multicenter study.

Author

Yekeduz, Emre, primary, Ozbay, Mehmet Fatih, additional, Çağlayan, Dilek, additional, Yıldırım, Atila, additional, Erol, Cihan, additional, Yıldırım, Hasan Çağrı, additional, Tunç, Sezai, additional, Özyurt, Neslihan, additional, Ozdemir, Feyyaz, additional, Sendur, Mehmet Ali Nahit, additional, Isikdogan, Abdurrahman, additional, Kilickap, Saadettin, additional, Ürün, Yüksel, additional, Yalcin, Suayib, additional, Artac, Mehmet, additional, Coskun, Hasan Senol, additional, and Utkan, Gungor, additional

Published
2022
Full Text
View/download PDF

7. A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey

Author

Arican, Ali, Bozkurt, Tulin, Bozcuk, Hakan, Demirkan, Binnaz, Buyukberber, Suleyman, Alkis, Necati, Sanli, Ulus Ali, Camci, Celalettin, Yildiz, Mustafa, Yucel, Idris, Uygun, Kazim, Aslay, Isik, Demiray, Mutlu, Bese, Nuran Senel, Isikdogan, Abdurrahman, Bahat, Zumrut, Gemici, Cengiz, Ozdemir, Feyyaz, Ozdener, Fatih, and Pekin, Bahadir

Published
2014
Full Text
View/download PDF

10. Fifty-one Kaposi sarcoma patients

Author

Dogan, Mutlu, Dogan, Lutfi, Ozdemir, Feyyaz, Yildirim Ozdemir, Nuriye, Senol Coskun, Hasan, Yalcintas Arslan, Ulku, Ozal, Guze, Utkan, Gungor, Demirkazik, Ahmet, Aydin, Fazil, Zengin, Nurullah, and Icli, Fikri

Published
2010
Full Text
View/download PDF

11. The clinical importance of serum galectin-3 levels in breast cancer patients with and without metastasis

Author

Topcu, Turkan, Kavgaci, Halil, Gunaldi, Meral, Kocoglu, Hakan, Akyol, Murat, Mentese, Ahmet, Yaman, Serap, Orem, Asim, Ozdemir, Feyyaz, and Aydin, Fazil

Subjects
Lectins -- Health aspects, Breast cancer -- Genetic aspects -- Development and progression -- Care and treatment, Gene expression -- Health aspects, Health
Abstract

Byline: Turkan. Topcu, Halil. Kavgaci, Meral. Gunaldi, Hakan. Kocoglu, Murat. Akyol, Ahmet. Mentese, Serap. Yaman, Asim. Orem, Feyyaz. Ozdemir, Fazil. Aydin Objective: Studies have investigated expression status of galectin-3 (Gal-3), [...]

Published
2018

12. The clinical importance of serum urokinase plasminogen activator receptor and carbonic anhydrase IX levels and the effect of anthracycline-based adjuvant chemotherapy on these biomarkers in breast cancer

Author

Topcu, Turkan, Ozdemir, Feyyaz, Kavgaci, Halil, Gunaldi, Meral, Kocoglu, Hakan, Imamoglu, Goksen, Mentese, Ahmet, Yaman, Serap, Orem, Asim, and Aydin, Fazil

Subjects
Anthracyclines -- Usage, Urokinase -- Research, Carbonic anhydrase -- Research, Adjuvant chemotherapy -- Usage, Breast cancer -- Care and treatment, Biological markers -- Usage, Health
Abstract

Byline: Turkan. Topcu, Feyyaz. Ozdemir, Halil. Kavgaci, Meral. Gunaldi, Hakan. Kocoglu, Goksen. Imamoglu, Ahmet. Mentese, Serap. Yaman, Asim. Orem, Fazil. Aydin Introduction: Breast cancer mortality rates after metastasis is high. [...]

Published
2018

13. Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study

Author

Benekli, Mustafa, primary, Gumus, Mahmut, additional, Ozkan, Metin, additional, Dane, Faysal, additional, Elkiran, Emin T., additional, Cicin, Irfan, additional, Sevinc, Alper, additional, Aliustaoglu, Mehmet, additional, Isikdogan, Abdurrahman, additional, Meydan, Nezih, additional, Oksuzoglu, Berna, additional, Ozyilkan, Ozgur, additional, Artac, Mehmet, additional, Ozdemir, Feyyaz, additional, and Kilickap, Sadettin, additional

Published
2020
Full Text
View/download PDF

17. Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study.

Author

Benekli, Mustafa, Gumus, Mahmut, Ozkan, Metin, Dane, Faysal, Elkiran, Emin T., Cicin, Irfan, Sevinc, Alper, Aliustaoglu, Mehmet, Isikdogan, Abdurrahman, Meydan, Nezih, Oksuzoglu, Berna, Ozyilkan, Ozgur, Artac, Mehmet, Ozdemir, Feyyaz, and Kilickap, Sadettin

Subjects
RENAL cell carcinoma, CYTOKINES, DRUG efficacy, RESEARCH, SURVIVAL, HAND-foot syndrome, CONFIDENCE intervals, DIARRHEA, METASTASIS, MEDICAL cooperation, PROTEIN-tyrosine kinase inhibitors, CANCER patients, ASTHENIA, HOSPITAL wards, DESCRIPTIVE statistics, DRUG side effects, PATIENT safety, ONCOLOGY, LONGITUDINAL method, DRUG toxicity
Abstract

Objective: Cytokines have been the mainstay of treatment in metastatic renal cell cancer (mRCC) for decades before the introduction of tyrosine kinase inhibitors (TKIs), which dramatically changed the therapeutic landscape in these patients. This observational study was designed to evaluate use of TKIs in the treatment of cytokine-intolerant mRCC patients. Methods: A total of 151 cytokine-intolerant mRCC patients who were treated with TKIs (sunitinib, pazopanib and sorafenib) were enrolled in this prospective, non-interventional, multi-center observational study at 16 oncology centers across Turkey. Mean (SD) age was 61.3 (11.1) years and 74.8% were males. Data on duration of TKI treatment was the primary outcome measure. Additionally, overall response rate (ORR), progression free survival (PFS), overall survival (OS) and safety data were recorded. Results: Median duration of treatment was 8.2 months at a median follow up of 17.9 months. ORR and disease control rate were 12.5% and 70.8%, respectively. Median PFS and OS were 7.5 months (95%CI: 6.4–10.4) and 27.3 months (95%CI: 17.6–27.3) with no significant difference among three TKI agents in terms of treatment duration, ORR, PFS and OS. The most common adverse events excluding progression-which was the protocol requirement were diarrhea (13.6%), asthenia (13.6%) and hand-foot syndrome (12.6%). Dose modifications were required in 30.5% of the patients and 15% discontinued TKIs because of toxicity. Conclusions: Our findings confirm the efficacy and safety profile of TKIs in the first-line treatment of mRCC patients intolerant to cytokine treatment. There was no significant difference among three TKI agents in terms of treatment duration, ORR, PFS and OS. Trial registration: TURCOS ClinicalTrials.gov Identifier: NCT01585974. Registered April 25, 2012. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

20. Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia

Author

Sevinc,Alper, Ozkan,Metin, Ozet,Ahmet, Dane,Faysal, Oksuzoglu,Berna, Isikdogan,Abdurrahman, Ozdemir,Feyyaz, Uncu,Dogan, Gumus,Mahmut, Evrensel,Turkkan, Yaren,Arzu, Kara,Oguz, Tekin,Salim BaÅŸol, Sevinc,Alper, Ozkan,Metin, Ozet,Ahmet, Dane,Faysal, Oksuzoglu,Berna, Isikdogan,Abdurrahman, Ozdemir,Feyyaz, Uncu,Dogan, Gumus,Mahmut, Evrensel,Turkkan, Yaren,Arzu, Kara,Oguz, and Tekin,Salim BaÅŸol

Abstract

Alper Sevinç,1 Metin Özkan,2 Ahmet Özet,3 Faysal Dane,4 Berna ÖksüzoÄŸlu,5 Abdurrahman IşıkdoÄŸan,6 Feyyaz Özdemir,7 DoÄŸan Uncu,8 Mahmut GümüÅŸ,9 Türkkan Evrensel,10 Arzu Yaren,11 OÄŸuz Kara,12 Salim BaÅŸol Tekin13 1Department of Medical Oncology, Medical Park Gaziantep Hospital, Gaziantep, 2Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, 3Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, 4Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, 5Department of Medical Oncology, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, 6Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakır, 7Department of Medical Oncology, Karadeniz Technical University Faculty of Medicine, Trabzon, 8Department of Medical Oncology, Ankara Numune Hospital, Ankara, 9Department of Medical Oncology, Istanbul Medeniyet University, Istanbul, 10Department of Medical Oncology, UludaÄŸ University Faculty of Medicine, Bursa, 11Department of Medical Oncology, Pamukkale University Faculty of Medicine, Denizli, 12Department of Medical Oncology, Çukurova University Faculty of Medicine, Adana, 13Department of Medical Oncology, Atatürk University Faculty of Medicine, Erzurum, Turkey Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim in patients with chemotherapy-induced neutropenia.Patients and methods: This multicenter, observational study was conducted at 14 centers. The study included 337 patients experiencing neutropenia under chemotherapy. Patients were given either filgrastim 30 MIU or 48 MIU (Neupogen®) or biosimilar filgrastim 30 MIU (Leucostim®). Data regarding age, chemotherapeutic agents used, number of chemotherapy courses, previous diagnosis of neutropenia, neutrophil count of patient

Published
2018

23. Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia

Author

Sevinc, Alper, primary, Ozkan, Metin, additional, Ozet, Ahmet, additional, Dane, Faysal, additional, Oksuzoglu, Berna, additional, Isikdogan, Abdurrahman, additional, Ozdemir, Feyyaz, additional, Uncu, Dogan, additional, Gumus, Mahmut, additional, Evrensel, Turkkan, additional, Yaren, Arzu, additional, Kara, Oguz, additional, and Tekin, Salim Başol, additional

Published
2018
Full Text
View/download PDF

24. Effect of body mass index in gastric cancer patients Analysis of Turkish national gastric cancer registry

Author

Ciltas, Aydin, Karaca, Mustafa, Uncu, Dogan, Ozkan, Metin, Aliustaoglu, Mehmet, Tekin, Salim Basol, Cicin, Irfan, Kocer, Murat, Dane, Faysal, Oksuzoglu, Berna, Isikdogan, Abdurrahman, Ozdemir, Feyyaz, Elkiran, Emin Tamer, Karaoglu, Aziz, Yalcin, Bulent, Sevinc, Alper, Uysal, Mukremin, Boruban, C. E. M., Benekli, Mustafa, Buyukberber, Suleyman, Avci, Nilufer, Ozturk, Banu, Ulas, Arife, Turna, Hande, Ruchan Uslu, Dumanli, Esra, Abali, Huseyin, Kara, Oguz, and Gumus, Mahmut

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Turkish, Cancer, medicine.disease, Obesity, language.human_language, Cancer registry, Internal medicine, language, Medicine, business, Body mass index
Abstract

e15056 Background: Gastric cancer (GC) remains a common cancer in Turkey. There is increasing evidence of an association between obesity and risk of GC. Body mass index has been suggested to correl...

Published
2016

25. Outcomes of Turkish National Breast Cancer Registry.

Author

Kilickap, Saadettin, primary, Gumus, Mahmut, additional, Uncu, Dogan, additional, Ozkan, Metin, additional, Cicin, Irfan, additional, Elkiran, Tamer E., additional, Isikdogan, Abdurrahman, additional, Karaoglu, Aziz, additional, Oksuzoglu, Berna, additional, Ozdemir, Feyyaz, additional, Turna, Hande, additional, Uslu, Ruchan, additional, Ozyilkan, Ozgur, additional, Erdogan, Alper, additional, Goktas, Burce, additional, and Kara, Oguz, additional

Published
2017
Full Text
View/download PDF

26. Characteristics of Turkish colorectal cancer patients and bevacizumab preference.

Author

Cicin, Irfan, primary, Gumus, Mahmut, additional, Uncu, Dogan, additional, Ozkan, Metin, additional, Kilickap, Saadettin, additional, Elkiran, Tamer E., additional, Isikdogan, Abdurrahman, additional, Karaoglu, Aziz, additional, Oksuzoglu, Berna, additional, Ozdemir, Feyyaz, additional, Turna, Hande, additional, Kara, Oguz, additional, Ozyilkan, Ozgur, additional, Guducu, Merve, additional, Erdogan, Alper, additional, and Uslu, Ruchan, additional

Published
2017
Full Text
View/download PDF

27. Turkish National Colon Cancer Registry

Author

Benekli, Mustafa, Dumanli, Esra, Kilickap, Saadettin, Uncu, Dogan, Aliustaoglu, Mehmet, Cicin, Irfan, Gumus, Mahmut, Ozkan, Metin, Kocer, Murat, Karaoglu, Aziz, Dane, Faysal, Isikdogan, Abdurrahman, Elkiran, Tamer, Yalcin, Bulent, Uysal, Mukremin, Oksuzoglu, Berna, Boruban, Melih Cem, Ulas, Arife, Abali, Huseyin, Buyukberber, Suleyman, Tekin, Salim Basol, Avci, Nilufer, Sevinc, Alper, Ozdemir, Feyyaz, Ruchan Uslu, Turna, Hande, Ozturk, Banu, Kara, Oguz, and Kaya, Ali Osman

Subjects
Cancer Research, medicine.medical_specialty, business.industry, Colorectal cancer, Turkish, Incidence (epidemiology), Advanced stage, Cancer, medicine.disease, language.human_language, Oncology, Internal medicine, medicine, language, T-stage, Adenocarcinoma, business, Pathological
Abstract

e12646 Background: Colorectal cancers (CRC) have become the 3rd most common cancer in Turkey with increasing incidence over the years. Studies investigating the clinical and biologic features of CRC Turkey are small retrospective case series providing limited information. We initiated a Turkish National CRC Registry program in October 2012 to define clinical and pathological variables of CRC. Methods: Pts presenting to medical oncology clinics were prospectively registered in 28 centers nationwide. Pt demographics and clinicopathological characteristics were recorded. Results: 6143 pts (mean age 58.2±12.3) were analyzed (57% males). Mean ages of males were higher (59 vs 57 yrs, p = 0.001). Adenocarcinoma was the most common histology (97.8%). Initial stages at diagnosis: I (5.4%), II (29.6%), III (33.8%) and IV (20.2%), unknown (9.8%). Pts from Eastern Turkey were younger (56 vs 59, p < 0.001) with a more advanced stage (metastatic pts, 26.5% vs 18.4%). T stage was unknown in 22%, and T3 (46%) and T4 (20%...

Published
2015

28. Geographic variations of clinical characteristics in breast cancer: Analysis of Turkish National Breast Cancer Registry

Author

Kilickap, Saadettin, Altundag, Kadri, Dumanli, Esra, Gumus, Mahmut, Ruchan Uslu, Ozyilkan, Ozgur, Yalcin, Bulent, Kara, Oguz, Dogu, Gamze Gokoz, Ozturk, Banu, Kaya, Ali Osman, Aliustaoglu, Mehmet, Uncu, Dogan, Ozdemir, Feyyaz, Cicin, Irfan, Ozkan, Metin, Kocer, Murat, Turna, Hande, Buyukberber, Suleyman, Benekli, Mustafa, Coskun, Ugur, Karaoglu, Aziz, Tekin, Salim Basol, Dane, Faysal, Avci, Nilufer, Ulas, Arife, Oksuzoglu, Berna, Sevinc, Alper, Boruban, Melih Cem, and Çukurova Üniversitesi

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Turkish, education, Cancer, medicine.disease, language.human_language, Breast cancer, Internal medicine, language, Medicine, Presentation (obstetrics), business
Abstract

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, IL WOS: 000358036902450 … Amer Soc Clin Oncol

Published
2015

29. Association of age with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry

Author

Benekli, Mustafa, Altundag, Kadri, Dumanli, Esra, Isikdogan, Abdurrahman, Karaoglu, Aziz, Tekin, Salim Basol, Oksuzoglu, Berna, Kocer, Murat, Sevinc, Alper, Boruban, Melih Cem, Turna, Hande, Ruchan Uslu, Ozyilkan, Ozgur, Yalcin, Bulent, Coskun, Ugur, Kilickap, Saadettin, Dogu, Gamze Gokoz, Ozturk, Banu, Gumus, Mahmut, Buyukberber, Suleyman, Uncu, Dogan, Kara, Oguz, Aliustaoglu, Mehmet, Ozkan, Metin, Cicin, Irfan, Elkiran, E. Tamer, Dane, Faysal, Avci, Nilufer, Ulas, Arife, Ozdemir, Feyyaz, and Kaya, Ali Osman

Subjects
Cancer Research, Oncology
Published
2015

30. Changes in lifestyle upon diagnosis of cancer or other chronic illnesses: A Turkish Oncology Group study.

Author

Turhal, Nazim Serdar, Akinci, Figen, Haciabdullahoglu, Yasemin, Dolmaci, Makbule, Sari, Ayse, Gurhan, Nermin, Mutlu, Aylin, Ozdemir, Feyyaz, Artac, Mehmet, and Kilickap, Saadettin

Subjects
CHRONIC disease diagnosis, TUMOR diagnosis, BEHAVIOR modification, CANCER patient psychology, CANCER treatment, HEALTH behavior, HEALTH care rationing, MEDICAL needs assessment, SURVEYS, HEMODIALYSIS patients, WELL-being, SPECIALTY hospitals, PSYCHOLOGY
Abstract

Cancer, like other chronic illnesses, changes the patients’ way of living significantly. Although some may think, for instance, that religiousness would increase with the diagnosis of cancer, no previous studies have been performed in the Turkish society to confirm this. We, as the Turkish Oncology Group, conducted a survey in seven different oncology centres, representing a large majority of Turkey, to investigate how patients’ lifestyles changed following a cancer diagnosis; we used dialysis patients as a chronic illness control group. The study findings showed how changes in spiritual practices are completely in line with what is observed in other chronic illnesses. These findings may help to address cancer patients’ needs and facilitate resource allocation accordingly. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

34. Turkish National Breast Cancer Registry

Author

Altundag, Kadri, Dumanli, Esra, Aliustaoglu, Mehmet, Uncu, Dogan, Ozkan, Metin, Cicin, Irfan, Coskun, Ugur, Elkiran, Tamer, Kocer, Murat, Isikdogan, Abdurrahman, Karaoglu, Aziz, Tekin, Salim Basol, Avci, Nilufer, Ulas, Arife, Oksuzoglu, Berna, Ozdemir, Feyyaz, Kilickap, Saadettin, Gumus, Mahmut, Buyukberber, Suleyman, Benekli, Mustafa, Dane, Faysal, Sevinc, Alper, Boruban, Melih Cem, Turna, Hande, Ruchan Uslu, Ozyilkan, Ozgur, Yalcin, Bulent, Kara, Oguz, Dogu, Gamze Gokoz, Ozturk, Banu, and Kaya, Ali Osman

Subjects
Gynecology, Cancer Research, medicine.medical_specialty, business.industry, Turkish, Cancer, medicine.disease, humanities, language.human_language, Breast cancer, Oncology, Family medicine, Epidemiology, language, Medicine, business
Abstract

e12654 Background: Breast cancer (BC) is the most common cancer in women in Turkey. Studies investigating BC epidemiology in Turkey are retrospective case series providing limited information. We d...

Published
2015

38. Lack of Any Relationship between ABO and Rh Blood Groups and Clinicopathological Features in Patients with Gastrointestinal Stromal Tumors: Turkish Oncology Group

Author

Urun, Yuksel, primary, Utkan, Gungor, additional, Yalcin, Suayib, additional, CosKun, Hasan Senol, additional, Kocer, Murat, additional, Ozdemir, Nuriye Yildirim, additional, Kaplan, Mehmet Ali, additional, Arslan, Ulku Yalcintas, additional, Ozdemir, Feyyaz, additional, Oztuna, Derya, additional, Akbulut, Hakan, additional, and Icli, Fikri, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results